543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

BACKGROUND: DOR is a novel NNRTI that has shown noninferior efficacy to DRV+r- and EFV-based regimens in phase 3 trials (DRIVE-FORWARD [NCT02275780] and DRIVE-AHEAD [NCT02403674]). A prespecified integrated analysis of those trials plus a completed phase 2 trial (P007; NCT01632345) was performed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Melanie, Orkin, Chloe, Molina, Jean-Michel, Gatell, Jose, Sax, Paul, Cahn, Pedro, Squires, Kathleen, Zhou, Yan, Xu, Xia, Rodgers, Anthony, Kumar, Sushma, Teppler, Hedy, Martin, Elizabeth, Hanna, George, Hwang, Carey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255676/
http://dx.doi.org/10.1093/ofid/ofy210.551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255676/
http://dx.doi.org/10.1093/ofid/ofy210.551

Ejemplares similares